Acerand Therapeutics (Hong Kong) Ltd. has synthesized compounds acting as EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer.
S-Infinity Pharmaceuticals Co. Ltd. has disclosed azaquinoline ring-containing compounds acting as Tpl-2/Cot (MAP3K8) kinase inhibitors reported to be useful for the treatment of cancer, diabetes and inflammatory disorders.
Ubiquitin-specific proteases (USPs) play a crucial role in tumor progression, regulating the stability or functions of specific substrate proteins. USP33 expression is altered in several types of cancer, including ovarian cancer, pancreatic cancer and glioma.
Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer.
Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.
Intriguing scientific data continue to roll out in the head and neck cancer space, where the need for therapies has spurred a number of drug firms to try new approaches, which BioWorld examines in part two of a series that began in the Dec. 30 issue.
In a deal worth up to $1 billion, Ideaya Biosciences Inc. is in-licensing Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s SHR-4849, a phase I DLL3-targeting opo-I-payload antibody-drug conjugate (ADC). Under terms of the deal, San Francisco-based Ideaya will develop and commercialize SHR-4849 worldwide outside of greater China, and Shanghai-based Hengrui is eligible to receive up to $1.04 billion that includes a $75 million up-front fee, $200 million in development and regulatory milestone payments, and commercial success-based milestone payments. Hengrui is also eligible to receive royalties on net sales outside of greater China.
From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said during the Chinabio Partnering Forum in Shanghai in September.
RSS
